Was Competitive Landscape And Market Insight

"Wiskott Aldrich syndrome - Competitive Landscape and Market Insight, 2018", report provides comprehensive Insight about pipeline drugs along with technologies involved across this indication. The report provides the detailed analysis of marketed as well as pipeline products along with the companies involved. The report covers the Market Scenario till 2027, Attribute analysis, Product Potential Analysis, Wiskott Aldrich syndrome Market Evolution, and Unmet Needs. This report further provides comprehensive Insight about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis along with forecasted sales for upcoming launches.

Products covered by Phase

• Phase III and Phase II

Overview of pipeline development activities for Wiskott Aldrich syndrome

Pipeline analysis of the therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.


Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.


Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope

• The report provides competitive pipeline landscape of Wiskott Aldrich syndrome

• The report provides the marketed drugs information including its sales, development activities and details of patent expiry

• The report provides the insight of current and future market for Wiskott Aldrich syndrome

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Wiskott Aldrich syndrome pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Wiskott Aldrich syndrome and also provide company profiling

• Pipeline products coverage based on various stages of development ranging from late stage till mid stage

• Provides attribute analysis Report also covers the Attribute analysis, Product Potential Analysis, Wiskott Aldrich syndrome Market Evolution, Market Scenario, and Unmet Needs

Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Establish a comprehensive understanding of the current pipeline scenario across Wiskott Aldrich syndrome to formulate effective R&D strategies

• Assess challenges and opportunities that influence Wiskott Aldrich syndrome R&D

• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

• Devise corrective measures for pipeline projects by understanding Wiskott Aldrich syndrome pipeline depth and focus of Indication therapeutics

• Developing strategic initiatives to support your drug development activities

• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Wiskott Aldrich syndrome to enhance and expand business potential and scope

• Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies

• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Introduction

Executive Summary

Wiskott-Aldrich Syndrome (WAS)

Overview

Clinical Features

Pathophysiology

Signs and Symptoms

Diagnosis

Treatment

Epidemiology Overview - 7MM, 2015-2027

Prevalence of Wiskott-Aldrich Syndrome in 7MM

Epidemiology of Wiskott-Aldrich Syndrome in 7 MM

Assumptions and Rationale

Prevalent Population of Wiskott-Aldrich Syndrome in 7MM

Incident Population of Wiskott-Aldrich Syndrome in 7MM

Competitive Landscape

Pipeline Scenario

Late Stage Products (Phase III)

Comparative Analysis

GSK2696275: GlaxoSmithKline

Product Description

Research and Development

Heat Map

Product Development Activities

GSK2696275, 7MM Forecasted Sales

GSK2696275 – Analyst Insight

Mid-Stage Products

Comparative Analysis

Market Assessment

Wiskott-Aldrich Syndrome – Share Evolution

7MM Market Size of Wiskott-Aldrich Syndrome

Historical & Forecasted Market Size

Attribute Analysis

Analysis

Potential Matrix

Analysis

Unmet Need

Appendix

Table 1: Late Stage Products (Phase III)

Table 2: GSK2696275 Forecasted Sales (2020-2027)

Table 3: Mid Stage Products (Phase II)

Table 4: Drug 2 Forecasted Sales (2020-2027)

Table 5: Drug 3 Forecasted Sales (2021-2027)

Table 6: 7MM, Historical & Forecasted Prevalent Cases, 2015-2027

Table 7: 7MM, Historical & Forecasted Incident Cases, 2015-2027

Table 8: 7MM, Historical & Forecasted Market Size of Wiskott-Aldrich Syndrome, 2015-2027

Figure 1: Chromosomal Representation of Wiskott-Aldrich Syndrome protein (WASp)

Figure 2: Late Stage Products (Phase III)

Figure 3: GSK2696275 Forecasted Sales (2020-2027)

Figure 4: Mid Stage Products (Phase II)

Figure 5: Drug 2 Forecasted Sales (2020-2027)

Figure 6: Drug 3 Forecasted Sales (2021-2027)

Figure 7: 7MM, Historical & Forecasted Prevalent Cases, 2015-2027

Figure 8: 7MM, Historical & Forecasted Incident Cases, 2015-2027

Figure 9: 7MM, Historical & Forecasted Market Size of Wiskott-Aldrich Syndrome, 2015-2027

 

  • Tags:
  • WAS

Forward to Friend

Need A Quote